跳至主要内容
临床试验/ISRCTN88589234
ISRCTN88589234已完成3 期

Presurgical metformin for women with endometrial cancer: a randomised placebo controlled trial

Central Manchester University Hospitals NHS Trust (CMFT)0 个研究点目标入组 90 人开始时间: 2015年3月5日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
90

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Biopsy-proven type 1 endometrial carcinoma or severe atypical endometrial hyperplasia
  • 2. Scheduled surgical treatment by hysterectomy in 5-35 days’ time
  • 3. Informed consent
  • 4. Age 18 years or more

排除标准

  • 1. Current treatment with metformin
  • 2. Diabetic on hypoglycaemic medication
  • 3. Inability to consent due to lack of capacity or language barriers
  • 4. Unable to comply with treatment protocol
  • 5. Type 2 endometrial cancer
  • 6. Severe renal impairment (Serum creatinine >130umol/L or eGFR < 45ml/min/1.732m2)
  • 7. Severe hepatic impairment (abnormal LFTs to be discussed on case by case basis with hepatologist)
  • 8. Current alcohol abuse
  • 9. Sensitivity/hypersensitivity to biguanides
  • 10. Current treatment with other mTOR inhibitors or chemotherapeutic agents

研究者

发起方
Central Manchester University Hospitals NHS Trust (CMFT)

相似试验